Table 1.
Overview of small-molecules targeting mouse double minute 2 (MDM2) in clinical trials.
| Drug | Phases | NCT Number | Status | Conditions |
|---|---|---|---|---|
| RG7211 | Phase 1 | NCT00559533 | Completed | Neoplasms |
| RG7211 | Phase 1 | NCT00623870 | Completed | Hematologic neoplasms |
| RG7211 | Phase 1 | NCT01143740 | Completed | Sarcoma |
| RG7211 | Phase 1 | NCT01164033 | Completed | Neoplasms |
| RG7211 | Phase 1 | NCT01605526 | Completed | Sarcoma |
| RG7211 | Phase 1 | NCT01635296 | Completed | Myelogenous leukemia, acute |
| RG7211 | Phase 1 | NCT01677780 | Completed | Myelogenous leukemia, chronic, neoplasms, myelogenous leukemia, acute |
| RG7388 | Phase 1 | NCT01462175 | Completed | Neoplasms |
| RG7388 | Phase 1 | NCT01773408 | Completed | Myelogenous leukemia, acute |
| RG7388 | Phase 1 | NCT01901172 | Completed | Neoplasms |
| RG7388 | Phase 3 | NCT02545283 | Recruiting | Leukemia, myeloid, acute |
| RG7388 | Phase 1|phase 2 | NCT02633059 | Recruiting | Loss of chromosome 17p|recurrent plasma cell myeloma |
| RG7388 | Phase 1|phase 2 | NCT02670044 | Recruiting | Leukemia, myeloid, acute |
| RG7388 | Phase 1|phase 2 | NCT03135262 | Active, not recruiting | Follicular lymphoma|lymphoma, large B-cell, diffuse |
| RG7388 | Phase 1|phase 2 | NCT03158389 | Recruiting | Glioblastoma, adult |
| RG7388 | Phase 1|phase 2 | NCT03337698 | Recruiting | Carcinoma, non-small-cell lung |
| RG7388 | Phase 1 | NCT03362723 | Completed | Solid tumors |
| RG7388 | Phase 1|phase 2 | NCT03555149 | Recruiting | Colorectal cancer |
| RG7388 | Phase 1|phase 2 | NCT03566485 | Active, not recruiting | Stage III breast cancer|stage IIIA breast cancer|stage IIIB breast cancer|stage IIIC breast cancer|stage IV breast cancer|estrogen receptor-positive|HER2/Neu negative |
| RG7388 | Phase 1|phase 2 | NCT04029688 | Recruiting | AML|ALL|neuroblastoma|solid tumors |
| RG7775 | Phase 1 | NCT02098967 | Completed | Neoplasms, myelogenous leukemia, acute |
| SAR405838 | Phase 1 | NCT01636479 | Completed | Neoplasm malignant |
| SAR405838 | Phase 1 | NCT01985191 | Completed | Neoplasm malignant |
| HDM201 | Phase 1 | NCT02143635 | Active, not recruiting | Advanced solid and hematological TP53wt tumors |
| HDM201 | Phase 1|phase 2 | NCT02343172 | Active, not recruiting | Liposarcoma |
| HDM201 | Phase 1 | NCT02601378 | Active, not recruiting | Uveal melanoma |
| HDM201 | Phase 1 | NCT02780128 | Recruiting | Neuroblastoma|cancer |
| HDM201 | Phase 1 | NCT02890069 | Recruiting | Colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma |
| HDM201 | Phase 1 | NCT03714958 | Recruiting | Colorectal cancer|advanced cancer|metastatic cancer |
| HDM201 | Phase 1|phase 2 | NCT03760445 | Recruiting | Leukemia, myeloid, acute |
| HDM201 | Phase 1 | NCT03940352 | Recruiting | AML|high-risk MDS |
| HDM201 | Phase 2 | NCT04116541 | Not yet recruiting | Malignant solid tumor |
| APG-115 | Phase 1 | NCT02935907 | Recruiting | Patients with advanced solid tumor or lymphoma |
| APG-115 | Phase 1|phase 2 | NCT03611868 | Recruiting | Unresectable or metastatic melanoma or advanced solid tumors |
| APG-115 | Phase 1|phase 2 | NCT03781986 | Not yet recruiting | Malignant salivary gland cancer |
| AMG-232 | Phase 1 | NCT01723020 | Completed | Advanced malignancy|advanced solid tumors|cancer|oncology|oncology patients|tumors|glioblastoma|multiple myeloma |
| AMG-232 | Phase 1 | NCT02016729 | Completed | Advanced Malignancy|cancer|oncology|oncology Patients|AML |
| AMG-232 | Phase 1|phase 2 | NCT02110355 | Completed | Advanced malignancy|advanced solid tumors|cancer|oncology|oncology patients|tumors|melanoma |
| AMG-232 | Phase 1 | NCT03031730 | Recruiting | Hypercalcemia|plasmacytoma|recurrent plasma cell myeloma|refractory plasma cell myeloma |
| AMG-232 | Phase 1 | NCT03041688 | Recruiting | AML|recurrent AML|refractory AML|secondary AML |
| AMG-232 | Phase 1 | NCT03107780 | Recruiting | Glioblastoma|gliosarcoma|recurrent glioblastoma |
| AMG-232 | Phase 1 | NCT03217266 | Recruiting | Soft tissue sarcoma |
| AMG-232 | Phase 2 | NCT03662126 | Recruiting | PMF|Post-PV-MF|Post-ET-MF |
| AMG-232 | Phase 2 | NCT03669965 | Recruiting | Polycythemia vera |
| AMG-232 | Phase 2 | NCT03787602 | Recruiting | Merkel cell carcinoma |
| AMG-232 | Phase 1|phase 2 | NCT04113616 | Recruiting | AML|AML, secondary to MPN |
| AMG-232 | Phase 1 | NCT04190550 | Not yet recruiting | AML|AML arising from previous MDS |
| MK-8242 | Phase 1 | NCT01451437 | Terminated | AML |
| MK-8242 | Phase 1 | NCT01463696 | Terminated | Solid tumors |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; PMF, primary myelofibrosis; Post-PV-MF, post-polycythemia vera MF; Post-ET-MF, post-essential thrombocythemia MF; MPN, myeloproliferative neoplasms.